Clinical trials: pMMR
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Colorectal Cancer
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
The purpose of this study is to learn if combination of the two drugs regorafenib and nivolumab is an effective treatment for pMMR - MSS colorectal cancer, a special type of cancer of the colon or rectum (pMMR stands for…
- Trial name
- NCT04126733
- Testing
- Regorafenib (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bayer
Refractory Metastatic Colorectal Cancer, pMMR
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair…
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Trial name
- NCT05733611
- Testing
- RP2, RP3, atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Replimune, Inc.
Endometrial Neoplasms, Endometrial Cancer
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy.
- Trial name
- NCT07578649
- Testing
- PF-08634404, Pembrolizumab, Standard of Care Chemotherapy
- Where
- 54 sites in United States, Australia and 3 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Colorectal Cancer
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
This is a randomized, double-blind, phase III clinical trial. The study aims to demonstrate that the treatment regimen of Enlituo® plus FOLFOX is equivalent to that of Erbitux® plus FOLFOX in participants with RAS/BRAF wild-type…
- Trial name
- NCT07595276
- Testing
- Enlituo®, Erbitux®
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Colorectal Cancer with Hepatic Metastases
TATE and KN046 in MCRC
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc…
- Trial name
- NCT06834399
- Testing
- KN046 （PD-L1/CTLA4 BsAb）, TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Refractory Metastatic Colorectal Cancer, Solid Tumor
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients.
- Conditions
- Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient
- Trial name
- NCT05205330
- Testing
- CR6086, AGEN2034
- Where
- 3 sites in Italy
- Volunteers
- 107 people
- Sponsor
- Rottapharm Biotech
Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg/kg IV infusion Q3W, in…
- Conditions
- Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy
- Trial name
- NCT07244705
- Testing
- ABT-301, Tislelizumab, Bevacizumab (Avastin)
- Where
- 15 sites in Australia, Taiwan
- Volunteers
- 66 people
- Sponsor
- Anbogen Therapeutics, Inc.
Endometrial Cancer
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line…
- Trial name
- DUOLife (NCT06890273)
- Where
- 49 sites in Germany
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Colorectal Cancer
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.
- Trial name
- NCT06497985
- Testing
- Tucidinostat, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Metastatic Colorectal Cancer
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer…
- Trial name
- NCT07079631
- Testing
- BNT314, Pumitamig, SoC chemotherapy treatment 1
- Where
- 14 sites in United States, Germany and 3 more
- Volunteers
- 482 people
- Sponsor
- BioNTech SE
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Colorectal Cancer
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
This is an open label, multicenter Phase Ib/II clinical study on the efficacy and safety of AK119 and AK112 in combination with or without chemotherapy, and AK112 monotherapy in pMMR/MSS CRC
- Trial name
- NCT05846867
- Testing
- AK119, AK112, Oxaliplatin
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Akeso
First-line pMMR Endometrial Cancer
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer
This is a multicenter, randomized, double-blind, placebo controlled Phase III clinical trial, aiming to evaluate the efficacy and safety of HB0025 combined with chemotherapy (paclitaxel plus carboplatin) versus placebo combined…
- Trial name
- NCT07902999
- Testing
- HB0025 Injection, Paclitaxel injection, Carboplatin injection
- Where
- 2 sites in China
- Volunteers
- 333 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Locally Advanced Rectal Cancer
Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer
This is a randomized, double-blind, controlled, Phase III clinical study to evaluate the efficacy and safety of sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy…
- Trial name
- NCT07917468
- Testing
- Oxaliplatin, radiotherapy, Capecitabine
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced or Recurrent Endometrial Cancer
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
This is a phase IIIb, interventional, single arm, multicentre study assessing the safety profile of durvalumab in combination with carboplatin-paclitaxel chemotherapy followed by durvalumab with olaparib as first-line treatment…
- Trial name
- DUoENDE (NCT06746116)
- Testing
- Durvalumab + Chemotherapy phase, Durvalumab + Olaparib phase
- Where
- 24 sites in Spain
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 67 sites in United States, China and 2 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Colorectal Cancer
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
- Trial name
- STELLAR-316 (NCT07750158)
- Testing
- Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 13 sites in United States
- Volunteers
- 600 people
- Sponsor
- Exelixis
CRC (Colorectal Cancer)
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal…
- Trial name
- NCT07133750
- Testing
- PM8002, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 11 sites in China
- Volunteers
- 100 people
- Sponsor
- Biotheus Inc.